We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| NVIDIA Corporation | NASDAQ:NVDA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 32.04 | 3.61% | 919.93 | 919.88 | 920.30 | 922.20 | 890.59 | 893.90 | 37,310,962 | 00:11:43 |
From Nov 2023 to May 2024
By Nina Kienle
Roche Holding's Genentech and U.S. chip giant Nvidia have entered into a multiyear artificial-intelligence research collaboration to accelerate drug discovery and development.
California-based biotechnology company Genentech said Tuesday that the collaboration aims to combine its AI capabilities with Nvidia's computing expertise. It specifically looks to create a next-generation AI platform and, through that, improve or enhance Nvidia's platforms in return, Genentech said.
AI could boost the success rate of drug research and development over the long term, Genentech said.
Genentech said it will control the sharing of its proprietary data and Nvidia won't have direct access to them unless granted for use in a particular project.
Write to Nina Kienle at nina.kienle@wsj.com
(END) Dow Jones Newswires
November 21, 2023 10:51 ET (15:51 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year NVIDIA Chart |
1 Month NVIDIA Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
